News and Events

  • Overworked staff? The T-TAS® 01 platelet function analyzer can lighten the burden

    Posted: October 18, 2022

    It’s Not Just Support. It’s Solutions. T-TAS® 01 PL Assay: One test, one result, one total answer for platelet function Help address staffing and budgetary challenges with a frontline test for overall total platelet function Single assay with easy-to-interpret test result provides simple and comprehensive platelet reactivity status Consolidate testing from multiple platforms, for better…

    Read More

  • Go further than FEV1 and FVC – Mechanistic Biomarkers for Lung Disease

    Posted: October 11, 2022

    It’s Not Just Support. It’s Solutions. A Case for Letting Endotype Lead the Way in Drug Development…   Neutrophilic      VS      Eosinophilic The molecular mechanisms that drive chronic lung disease are heterogenetic. To evolve past a “one drug fits all approach”, toward a more individualized and precision approach, pharmaceutical companies are focusing…

    Read More

  • THSNA 2022 Recap

    Posted: October 7, 2022

    Chicago, IL, August 15-18, 2022   David L. McGlasson, MS, MLS(ASCP) The recent THSNA 2022 meeting that was held in Chicago, IL from August 15-18, 2022, was a welcome event, as attendees for the first time in a couple of years could attend the conference in person or virtually.  Finally, attendees had the ability to…

    Read More

  • Factor XIII Assays to Fit Your Needs

    Posted: September 30, 2022

    t’s Not Just Support. It’s Solutions. Factor XIII Activity Assays – The Right Fit for your Needs Manual and automated solutions for measuring FXIII Activity Technofluor® Factor XIII Fully automated on the Ceveron s100 for the determination of FXIII activity levels. Minimal hands-on time Data in under 30 minutes Single calibration per lot No need…

    Read More

  • Endotyping for Clinical Trial Success with COPD, bronchiectasis, asthma

    Posted: September 29, 2022

    It’s Not Just Support. It’s Solutions. Endpoints for clinical trials in lung disease could be better… FEV1 and FVC are relatively blunt tools for getting a complete picture of a disease state – they do not provide information on the pulmonary microenvironment. Inflammation is a hallmark of chronic lung diseases and an important piece of…

    Read More

  • Measure fibrosis in a more meaningful way using TOTAL collagen assays

    Posted: September 28, 2022

    It’s Not Just Support. It’s Solutions. Let DiaPharma introduce you to a new partner in fibrosis research, QuickZyme Biosciences DiaPharma is excited to announce that we now offer QuickZyme products. QuickZyme knows, “Matrix Matters”. Collagens are a main component of the extracellular matrix and are the most abundant proteins in the body. Collagens play important…

    Read More

  • VACCINE-INDUCED THROMBOTIC THROMBOCYTOPENIA (VITT): INSIGHTS FROM ISTH 2022

    Posted: September 26, 2022

    – Contributed by Abi Kasberg, PhD Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare and severe complication of adenoviral-based COVID-19 vaccinations. VITT occurs at a rate of 1:100,000 to 1:1,000,000 and is associated with high morbidity and mortality. Long term complications of VITT and VITT antibodies can persist for more than 9 months and has…

    Read More

  • Tools for Sickle Cell Disease Research

    Posted: September 22, 2022

    It’s Not Just Support. It’s Solutions. Tools for Sickle Cell Disease Research September is National Sickle Cell Awareness Month. From Anti-Hemoglobin S antibodies, coagulation kits, and biomarker assays, to exciting new instrumentation for clotting analysis, DiaPharma has what matters covered for impactful Sickle Cell research. Research projects like gene therapy require many decisions, including investigating…

    Read More

  • Time to include Human TSP2 in your next NASH study?

    Posted: September 14, 2022

    It’s Not Just Support. It’s Solutions.   Time to include Thrombospondin-2 in your next NASH study… Thrombospondin-2 has been identified by transcriptomics as an emerging NASH biomarker. Protein analysis shows that it has promise for use in studying NAFLD, NASH, metabolic disease, and diabetes. This Human TSP2 ELISA kit, from ImmunoDiagnostics, is proven reliable for…

    Read More

  • Emerging Therapeutic Targets for Hereditary Angioedema

    Posted: August 31, 2022

    -Contributed by Abi Kasberg, PhD Hereditary Angioedema (HAE) is a rare, inherited, autosomal dominant disorder that is characterized by fluid accumulation and tissue swelling that can be painful and potentially life-threatening. This form of angioedema is driven by vasculature leakage into surrounding tissues including in the hands, feet, lips, genitals, gastrointestinal tract, or airway. Normal…

    Read More

  • What’s New at DiaPharma?

    Posted: August 15, 2022

    It’s Not Just Support. It’s Solutions. Meet Genesis Cautivar West Territory Manager Genesis Cautivar joined DiaPharma in July 2022. He is a native of Vancouver, British Columbia, Canada and currently resides in the Dallas-Fort Worth, Texas Metroplex. He received his B.S. in Medical Technology from Walla Walla University (WA). He has many years of experience…

    Read More

  • Exploratory Biomarkers for Acute and Chronic Kidney Injury Studies

    Posted: June 28, 2022

    It’s Not Just Support. It’s Solutions. Spotlight on Acute and Chronic Kidney Injury Enhanced assays with improved sensitivity and specificity to assist in kidney disease studies L-FABP ● NGAL ● Osteopontin ● alpha-GST ● Cystatin C ● RBP4 ● Anti-EHEC There are large gaps in the information that standard kidney markers, like serum creatinine, can…

    Read More

  • CHROMOGENIC FACTOR X ASSAYS vs the PT/INR TO MONITOR SUBJECTS ON COUMADIN THERAPY WHEN AN INDIVIDUAL APPROACH IS NECESSARY

    Posted: June 28, 2022

    INTRODUCTION In a previous CLOT CLUB blog post I discussed how chromogenic factor X assays (CFX) were more accurate and less likely to be influenced in certain instances than using the prothrombin time/international ratio assay (PT/INR)1.  The PT/INR may be falsely elevated in the presence of lupus anticoagulants (LA), direct thrombin inhibitors (DTI), and dysfibrinogenemia. …

    Read More

  • News from the front lines at SOT 2022: Checkpoint Inhibitor Liver Toxicity

    Posted: June 7, 2022

    It’s Not Just Support. It’s Solutions.   Spotlight on Liver Toxicity: Immune-mediated Liver Injury Caused by Checkpoint Inhibitors (ILICI) One thing that jumped out at the Society of Toxicology (SOT) meeting this past March was a new phase of liver toxicology research focused on therapies that have a direct effect on immune function, specifically, hepatotoxicity…

    Read More

  • Measure True Beta Cell Dysfunction with TECO Intact Proinsulin

    Posted: June 6, 2022

    It’s Not Just Support. It’s Solutions. When it comes to measuring pancreatic Beta cell function, go with the Pro! TECO® Intact Proinsulin ELISA Save time and guess work by selectively measuring only intact proinsulin. Proinsulin is synthesized in pancreatic β-cells and secreted as insulin. Insulin resistance (IR) or hyperglycemia causes increased secretion and finally secretion…

    Read More

  • T-TAS®01 – The Leading Edge in Platelet Thrombus Formation Assessment

    Posted: June 1, 2022

    It’s Not Just Support. It’s Solutions. Innovative Total Platelet Function Analysis using Whole Blood Global evaluation of overall hemostatic ability using physiologic, flow conditions Exclusively from DiaPharma. Advantages of T-TAS® 01 PL Assay Ease of Interpretation A numeric cut-off easily identifies those with primary hemostasis disorders, assisting with more timely determination of appropriate treatment strategy…

    Read More

  • Respiratory Research Solutions from DiaPharma

    Posted: May 16, 2022

    It’s Not Just Support. It’s Solutions. DiaPharma is Your Exclusive Source for ProAxsis products   Reach out to DiaPharma’s Olivia Stricker, who will be at American Thoracic Society (ATS) 2022 in San Francisco, May 13 – 16. Elevate your clinical research data by measuring active proteases Targets: Drug development evaluating new protease inhibitors or anti-inflammatory…

    Read More

  • Comprehensive Solutions for Anticoagulation Research

    Posted: May 9, 2022

    It’s Not Just Support. It’s Solutions. Explore Assays from DiaPharma to Enhance Your Anticoagulation Research Whether you’re researching vitamin K antagonists, thrombin inhibitors, FXa inhibitors, or contact pathway inhibitors, you need reliable, relevant tests. DiaPharma can help you select the right assays. Thrombin Generation Testing Manual or automated options for studying potential new anticoagulants Technothrombin® TGA*…

    Read More

  • Immune-mediated Liver Injury caused by Checkpoint Inhibitors (ILICI)

    Posted: May 5, 2022

    -Contributed by Abi Kasberg, PhD The immune checkpoint is a vital regulatory component that prevents the immune system from targeting healthy cells or developing autoimmunity. It does so via immunoreceptors that suppress T cell activity in mechanisms that protect normal, healthy cells from destruction. However, prolonged expression of immune checkpoint proteins can lead to T…

    Read More

  • What’s New at DiaPharma?

    Posted: April 28, 2022

    It’s Not Just Support. It’s Solutions. Meet Ryan McCaw Midwest Territory Manager Ryan joined DiaPharma in January of 2022. He obtained his BS in Medicine from the University of Iowa where he also completed the Medical Technology program. He was certified as a Medical Technologist with the ASCP and started his career in medical research…

    Read More